Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials

Abstract

IntroductionThe present study aims to evaluate the risk of pancreatic cancer with incretin-based therapy among patients with type 2 diabetes mellitus (T2DM).MethodsWe searched EMBASE, MEDLINE, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov for eligible studies published up to March 06 2016. This meta-analysis includes all studies reporting adverse events of pancreatic cancer with use of incretin-based therapies compared with placebo or non-incretin anti-diabetic drugs in patients with T2DM. We used fixed-effect model to compare pooled relative risk (RR) with related 95% confidence intervals (CI).ResultsA total of 159 randomized trials were identified. Out of these, 135 studies were excluded as pancreatic cancer occurrence had not been included as an end point. The remaining 24 trials enrolling 47,904 participants were further assessed. Overall, no increased risk of pancreatic cancer were detected in association with incretin-based treatment (RR = 0.7, 95% CI 0.37–1.05). The incidence of pancreatic neoplasm was even lower among incretin-based groups than controls (RR = 0.50, 95% CI 0.29–0.87) in trials with duration more than 104 weeks. There was even decreased risk of pancreatic cancer within groups paralleled by incretin-matched placebos (RR = 0.55, 95% CI 0.32–0.93) than by non-incretin anti-diabetic drugs. Neither monotherapy (RR = 0.62, 95% CI 0.38–1.01) nor combination regimen (RR = 0.92, 95% CI 0.45–1.90) of incretin mimetics increased the risk of pancreatic cancer.ConclusionThis meta-analysis shows that incretin-based therapies are not associated with increase in the risk of pancreatic cancer. Interestingly, subgroup analyses suggested lower risk of pancreatic cancer in incretin groups than placebo in long-term studies (>104 weeks). Considering the inconsistent results among randomized trials and previous epidemiological investigations, more such studies should be conducted to clarify the existence or non-existence of this association.FundingThis work was supported by grants from the National Natural Science Foundation of China (Nos. 81270476 and 81470830).Electronic supplementary materialThe online version of this article (doi:10.1007/s13300-016-0198-3) contains supplementary material, which is available to authorized users.

Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study

“…For pancreatic cancer, our findings are qualitatively consistent with results reported by Romley et al, Gokhale et al, Azoulay et al, Dore et al and Funch et al as well as a recent meta‐analysis of 24 clinical trial studies. However, the results differ from those reported by Elashoff et al, Boniol et al and Tseng .…”

Risk of dipeptidyl peptidase‐4 (DPP‐4) inhibitors on site‐specific cancer: A systematic review and meta‐analysis

“…In 2014, a joint study was published in the New England Journal of Medicine , stating that the agencies had not yet reached a final conclusion regarding a possible relationship . Since then, several literature reviews have been conducted regarding incretin‐based drugs and pancreatic cancer …”

Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti‐hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes

“…Although a number of cohort studies and meta‐analyses reported no association between incretin‐based therapies and risk of acute pancreatitis and pancreatic cancer , other studies have reported an increased risk of acute pancreatitis with such agents . In a meta‐analysis based on pooled data from the SAVOR‐TIMI 53, EXAMINE and TECOS trials, Tkáč and Raz reported a significant increase in the incidence of acute pancreatitis [odds ratio (OR): 1.79; 95% confidence intervals (CI) 1.13, 2.82] in people treated with DPP‐4i when compared with placebo.…”